Background: Flavonoids are documented for their potential anti-adipogenic, anti-inflammatory and anti-diabetic effects. Quercetin, one of the most abundant flavonoids in edible plants, was investigated for these effects in a diabetic mouse model (db/db, leptin receptor mutation) exerting early relevant clinical signs of non-insulin dependent diabetes mellitus, such as hyperglycemia, hyperinsulinemia, hypertriglyceridemia, hypoadiponectinemia and obesity. Materials & Methods: Female db/db mice (n = 24) were fed a flavonoid-poor maintenance diet without (C) or with the addition of quercetin (0.3 g/kg diet, Q) or rosiglitazone (4 mg/kg diet, TZD). Food and water were freely available during the 4 week feeding period. Thereafter, blood samples (fasted) were analyzed for glucose, insulin, triacylglycerols, non-es terified fatty acids, cholesterol, adiponectin and soluble intercellular adhesion molecule-1 (sICAM-1). Adiponectin mRNA levels were measured in adipose tissue. Furthermore, sICAM-1 release was investigated using tumor necrosis factor alpha stimulated EAhy926 cells. Results: Only TZD treatment reduced fasted plasma glucose, triacylglycerols and cholesterol and increased plasma adiponectin concentrations compared to groups C and Q. Adiponectin mRNA levels after quercetin treatment were not different from TZD-treatment or controls. Only quercetin treatment reduced sICAM-1 release in vitro and in vivo . Conclusions: Quercetin effectively reduced sICAM-1 release in the progressive diabetic state, revealing its anti-inflammatory potential in vivo .
V. Vachharajani and D. N. Granger, “Adipose Tissue: A Motor for the Inflammation Associated with Obesity,” IUBMB Life, Vol. 61, No. 4, 2009, pp. 424-430. doi:10.1002/iub.169
H. K. Vincent and A. G. Taylor, “Biomarkers and Potential Mechanisms of Obesity-Induced Oxidant Stress in Humans,” International Journal of Obesity, Vol. 30, No. 3, 2006, pp. 400-418. doi:10.1038/sj.ijo.0803177
J. Spranger, A. Kroke, M. Mohlig, M. M. Bergmann, M. Ristow, H. Boeing and A. F. Pfeiffer, “Adiponectin and Protection against Type 2 Diabetes Mellitus,” Lancet, Vol. 361, No. 9353, 2003, pp. 226-228. doi:10.1016/S0140-6736(03)12255-6
P. Dandona, A. Aljada and A. Bandyopadhyay, “Inflammation: The Link between Insulin Resistance, Obesity and Diabetes,” Trends in Immunology, Vol. 25, No. 1, 2004, pp. 4-7. doi:10.1016/j.it.2003.10.013
J. Constans and C. Conri, “Circulating Markers of Endothelial Function in Cardiovascular Disease,” Clinica Chimica Acta, Vol. 368, No. 1-2, 2006, pp. 33-47. doi:10.1016/j.cca.2005.12.030
A. J. H. Gearing, I. Hemingway, R. Pigott, J. Hughes, A. J. Rees and S. J. Cashman, “Soluble Forms of Vascular Adhesion Molecules, E-Selectin, ICAM-1, and VCAM-1— Pathological Significance,” Annals of the New York Academy of Sciences, Vol. 667, No. 1, 1992, pp. 324-331. doi:10.1111/j.1749-6632.1992.tb51633.x
E. Hu, P. Liang and B. M. Spiegelman, “AdipoQ Is a Novel Adipose-Specific Gene Dysregulated in Obesity,” Journal of Biological Chemistry, Vol. 271, No. 18, 1996, pp. 10697-10703. doi:10.1074/jbc.271.18.10697
N. Maeda, M. Takahashi, T. Funahashi, S. Kihara, H. Nishizawa, K. Kishida, H. Nagaretani, M. Matsuda, R. Komuro, N. Ouchi, H. Kuriyama, K. Hotta, T. Nakamura, I. Shimomura and Y. Matsuzawa, “PPARgamma Ligands Increase Expression and Plasma Concentrations of Adi-ponectin, an Adipose-Derived Protein,” Diabetes, Vol. 50, No. 9, 2001, pp. 2094-2099. doi:10.2337/diabetes.50.9.2094
L. P. Qiao, P. S. MacLean, J. Schaack, D. J. Orlicky, C. Darimont, M. Pagliassotti, J. E. Friedman and J. H. Shao, “C/EBPa Regulates Human Adipo-nectin Gene Transcription through an Intronic Enhancer,” Diabetes, Vol. 54, No. 6, 2005, pp. 1744-1754. doi:10.2337/diabetes.54.6.1744
M. Guerre-Millo, “Adiponectin: An Update,” Diabetes & Metabolism, Vol. 34, No. 1, 2008, pp. 12-18. doi:10.1016/j.diabet.2007.08.002
Z. Bagi, A. Koller and G. Kaley, “PPAR{gamma} Activation, by Reducing Oxidative Stress, Increases NO Bioavailability in Coronary Arterioles of Mice with Type 2 Diabetes,” AJP—Heart and Circulatory Physiology, Vol. 286, No. 2, 2004, pp. H742-H748.
C. R. Benton, G. P. Holloway, S. E. Campbell, Y. Yoshida, N. N. Tandon, J. F. C. Glatz, J. J. J. F. Luiken, L. L. Spriet and A. Bonen, “Rosiglitazone Increases Fatty Acid Oxidation and Fatty Acid Translocase (FAT/CD36) but Not Carnitine Palmitoyltransferase I in Rat Muscle Mitochondria,” Journal of Physiology-London, Vol. 586, No. 6, 2008, pp. 1755-1766. doi:10.1113/jphysiol.2007.146563
J. Wilding, “Thiazoli-dinediones, Insulin Resistance and Obesity: Finding a Balance,” International Journal of Clinical Practice, Vol. 60, No. 10, 2006, pp. 1272-1280. doi:10.1111/j.1742-1241.2006.01128.x
R. M. Viner, Y. Hsia, T. Tomsic and I. C. K. Wong, “Efficacy and Safety of Anti-Obesity Drugs in Children and Adolescents: Systematic Review and Meta-Analysis,” Obesity Reviews, Vol. 11, No. 8, 2010, pp. 593-602. doi:10.1111/j.1467-789X.2009.00651.x
J. Kennedy, “Herb and Supplement Use in the US Adult Population,” Clinical Therapeutics, Vol. 27, No. 11, 2005, pp. 1847-1858. doi:10.1016/j.clinthera.2005.11.004
E. Middleton, C. Kandaswami and T. C. Theoharides, “The Effects of Plant Flavonoids on Mammalian Cells: Implications for Inflammation, Heart Disease, and Cancer,” Pharmacological Reviews, Vol. 52, No. 4, 2000, pp. 673-751.
G. Williamson and C. Manach,. “Bioavailability and Bioefficacy of Polyphenols in Humans. II. Review of 93 Intervention Studies,” American Journal of Clinical Nutrition, Vol. 81, Suppl. 1, 2005, pp. 243S-255S.
O. Kwon, P. Eck, S. Chen, C. P. Corpe, J. H. Lee, M. Kruhlak and M. Levine, “Inhibition of the Intestinal Glucose Transporter GLUT2 by Flavonoids,” FASEB Journal, Vol. 21, No. 2, 2007, pp. 366-377. doi:10.1096/fj.06-6620com
X. K. Fang, J. Gao and D. N. Zhu, “Kaempferol and Quercetin Isolated from Euonymus alatus Improve Glucose Uptake of 3T3-L1 Cells without Adipo-genesis Activity,” Life Sciences, Vol. 82, No. 11-12, 2008, pp. 615-622. doi:10.1016/j.lfs.2007.12.021
Y. Kumazawa, K. Kawaguchi and H. Takimoto, “Immunomodulating Effects of Flavonoids on Acute and Chronic Inflammatory Responses Caused by Tumor Necrosis Factor Alpha,” Current Pharma-ceutical Design, Vol. 12, No. 32, 2006, pp. 4271-4279. doi:10.2174/138161206778743565
S. Wein, N. Behm, R. K. Petersen, K. Kristiansen and S. Wolffram, “Quercetin Enhances Adiponectin Secretion by a PPAR-Gamma Independent Mechanism,” European Journal of Pharmaceutical Sciences, Vol. 41, No. 1, 2010, pp. 16-22. doi:10.1016/j.ejps.2010.05.004
B. A. Graf, P. E. Milbury and J. B. Blumberg, “Flavonols, Flavones, Flavanones, and Human Health: Epidemiological Evidence,” Journal of Medicinal Food, Vol. 8, No. 3, 2005, pp. 281-290. doi:10.1089/jmf.2005.8.281
P. R. Johnson, M. R. C. Greenwood, B. A. Horwitz and J. S. Stern, “Animal-Models of Obesity—Genetic-Aspects,” Annual Review of Nutrition, Vol. 11, 1991, pp. 325-353. doi:10.1146/annurev.nu.11.070191.001545
C. J. Edgell, C. C. McDonald and J. B. Graham, “Permanent Cell Line Ex-pressing Human Factor VIII-Related Antigen Established by Hybridization,” Proceedings of the National Academy of Sciences of the USA, Vol. 80, No. 12, 1983, pp. 3734-3737. doi:10.1073/pnas.80.12.3734
K. Srinivasan and P. Rama-rao, “Animal Models in Type 2 Diabetes Research: An Overview,” Indian Journal of Medical Research, Vol. 125, No. 3, 2007, pp. 451-472.
J. Ahn, H. Lee, S. Kim, J. Park and T. Ha, “The Anti-Obesity Effect of Quercetin Is Mediated by the AMPK and MAPK Signaling Pathways,” Biochemical and Bio-physical Research Communications, Vol. 373, No. 4, 2008, pp. 545-549. doi:10.1016/j.bbrc.2008.06.077
P. J. Chien, Y. C. Chen, S. C. Lu and F. Sheu, “Dietary Flavonoids Suppress Adipogenesis in 3T3-L1 Preadipocytes,” Journal of Food and Drug Analysis, Vol. 13, No. 2, 2005, pp. 168-175.
M. Kobori, S. Masumoto, Y. Akimoto and H. Oike, “Chronic Dietary Intake of Quercetin Alleviates Hepatic Fat Accumulation Associated with Consumption of a Western-Style Diet in C57/BL6J Mice,” Molecular Nutrition & Food Research, Vol. 55, No. 4, 2011, pp. 530-540. doi:10.1002/mnfr.201000392
L. Rivera, R. Moron, M. Sanchez, A. Zarzuelo and M. Galisteo, “Quercetin Ameliorates Metabolic Syndrome and Improves the Inflammatory Status in Obese Zucker Rats,” Obesity, Vol. 16, No. 9, 2008, pp. 2081-2087. doi:10.1038/oby.2008.315
J. Barrenetxe, P. Aranguren, A. Grijalba, J. M. MartinezPenuela, F. Marzo and E. Urdaneta, “Effect of Dietary Quercetin and Sphingomyelin on Intestinal Nutrient Absorption and Animal Growth,” British Journal of Nutrition, Vol. 95, No. 3, 2006, pp. 455-461. doi:10.1079/BJN20051651
T. Mahesh and V. P. Menon, “Quercetin Allievates Oxidative Stress in Streptozotocin-Induced Diabetic Rats,” Phytotherapy Research, Vol. 18, No. 2, 2004, pp. 123-127. doi:10.1002/ptr.1374
A. K. Shetty, R. Rashmi, M. G. R Rajan, K. Sambaia and P. V. Salimath, “Antidiabetic Influence of Quercetin in Streptozotocin-Induced Diabetic Rats,” Nutrition Research, Vol. 24, No. 5, 2004, pp. 373-381.
J. K. Dunnick and J. R. Hailey, “Toxicity and Carcinogenicity Studies of Quercetin, a Natural Component of Foods,” Funda-mental and Applied Toxicology, Vol. 19, No. 3, 1992, pp. 423-431. doi:10.1016/0272-0590(92)90181-G
J. Wilding, “Thiazolidinediones, Insulin Resistance and Obesity: Finding a Balance,” International Journal of Clinical Practice, Vol. 60, No. 10, 2006, pp. 1272-1280. doi:10.1111/j.1742-1241.2006.01128.x
P. Tontonoz and B. M. Spiegelman, “Fat and Beyond: The Diverse Biology of PPAR Gamma,” Annual Review of Biochemistry, Vol. 77, 2008, pp. 289-312. doi:10.1146/annurev.biochem.77.061307.091829
O. Y. Kim, S. M. Lee, H. Do, J. Moon, K. H. Lee, Y. J. Cha and M. J. Shin, “Influence of Quercetin-Rich Onion Peel Extracts on Adipokine Expression in the Visceral Adipose Tissue of Rats,” Phytotherapy Research, Vol. 26, No. 3, 2011, pp. 432-437.
A. Hammarstedt, C. X. Andersson, S. V. Rotter and U. Smith, “The Effect of PPARgamma Ligands on the Adipose Tissue in Insulin Resistance,” Prostaglandins, Leuko-trienes and Essential Fatty Acids, Vol. 73, No. 1, 2005, pp. 65-75. doi:10.1016/j.plefa.2005.04.008
M. Comalada, D. Camuesco, S. Sierra, I. Ballester, J. Xaus, J. Galvez and A. Zarzuelo, “In Vivo Quercitrin Anti-Inflammatory Effect Involves Release of Quercetin, Which Inhibits Inflammation through Down-Regulation of the NF-kappaB Pathway,” European Journal of Immunology, Vol. 35, No. 2, 2005, pp. 584-592. doi:10.1002/eji.200425778
G. B. Moore, H. Chapman, J. C. Holder, C. A. Lister, V. Piercy, S. A. Smith and J. C. Clapham, “Differential Regulation of Adipocytokine mRNAs by Rosiglitazone in db/db Mice,” Biochemical and Biophysical Research Communications, Vol. 286, No. 4, 2001, pp. 735-741. doi:10.1006/bbrc.2001.5460
A. Suzuki, T. Yasuno, H. Kojo, J. Hirosumi, S. Mutoh and Y. Notsu, “Alteration in Expression Profiles of a Series of Diabetes-Related Genes in db/db Mice Following Treatment with Thiazolidinediones,” Japanese Journal of Pharmacology, Vol. 84, No. 2, 2000, pp. 113-123. doi:10.1254/jjp.84.113